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THE EFFECT OF TANGO DANCE ON SLEEP IN PARKINSON’S DISEASE 
ALIZAH MATEO 
ABSTRACT 
Among all symptoms of Parkinson’s Disease (PD), depression and sleep dysfunction 
have the highest impact on quality of life, yet sleep disturbances and depression 
symptoms are often left unrecognized and untreated. With the rising annual cost of 
pharmacologic treatments for PD and the increasing prevalence of PD in the United 
States, there is a need to implement effective non-pharmacologic regimens, such as 
physical exercise. Adherence to exercise regimens can often be challenging, especially 
for elderly patients with progressive neurological impairment. However, enjoyable 
exercises, such as dancing, involve socialization and musical stimuli that are associated 
with increased motivation in patients. Dance exercise has been shown to have significant 
improvement in motor symptoms, functional mobility, mood, and quality of life in PD 
patients compared to no intervention or traditional exercises. Previous studies have 
shown that Tango style dancing has additional benefits for PD patients as it may 
selectively activate areas of the brain associated with motor and non-motor symptoms 
(the basal ganglia and anterior putamen, respectively) during backward walking and 
metered rhythmic movement. However, no studies have yet investigated the effect of 
dance intervention on sleep quality in patients with PD. 
The proposed study is a randomized control trial that will compare the sleep 
quality improvement of 90 elderly PD patients in two treatment arms, a Tango dance 
intervention with walking and walking alone (control group). The Tango group will 
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participate in a 6-month Adapted Tango class designed for PD patients. Sleep quality will 
be measured as the primary outcome using the Parkinson’s Disease Sleep Scale (PDSS-
2). Depression will be measured as a secondary outcome using the BDI-II.  
This will be the first study to investigate the effects of dance intervention on sleep 
quality in patients with PD, applying an adapted Tango program similar to those used in 
previous studies. If the results of this study reveal positive effects of Tango on sleep 
quality, clinicians may be able to recommend Tango-style dance exercise as a therapeutic 
intervention to target sleep disturbances and improve quality of life for patients with PD. 
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INTRODUCTION 
Background 
Parkinson’s Disease (PD) is a neurodegenerative disease characterized by the loss of 
dopaminergic neurons in the substantia nigra pars compacta in the midbrain, leading to 
motor and non-motor impairment. PD is known to affect nearly 1 million patients in the 
US. With the projected growth of the aging population, that number is expected to double 
in the next 15-30 years.1 Several epidemiologic studies have identified risk factors 
involving genetic and environmental factors but the direct cause of cell death and 
impairment of the dopaminergic neurons is still unclear.  
Traditionally, PD was classified as a motor disorder but over time has been 
recognized as a more complex condition that further involves a range of nonmotor 
symptoms, including depression, anxiety, sleep disorders, cognitive decline, paresthesia, 
autonomic dysfunction and fatigue. An estimated 55-80% of patients with PD are 
affected by sleep difficulties.2 Patients with PD commonly experience sleep disorders 
such as sleep-onset insomnia (difficulty falling asleep), sleep-maintenance insomnia 
(difficulty remaining asleep), restless leg syndrome, and rapid eye movement (REM) 
sleep behavior disorder (RBD). Poor sleep quality, early morning awakening, and 
decreased sleep duration are also symptoms commonly associated with depression.3 
Depression is the most common psychiatric disturbance in PD, affecting up to 50% of 
patients.4 Clinically, depression is recognized by features such as anhedonia, loss of 
appetite, feelings of hopelessness, difficulty sleeping and cognitive deficits. The 
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complications of depression have a strong association with sleep dysfunction and may 
lead to worsening of other symptoms related to PD. 
 Because of the adverse side effects and limited effectiveness of drug therapy after 
prolonged use, the initiation of pharmacologic and surgical treatment is warranted only 
once symptoms become bothersome or disabling to patients. In order to minimize 
medication use, non-pharmacologic and non-surgical PD therapies become essential 
components of the broad-based treatment plan. The most optimal form of non-
pharmacologic and non-surgical therapy remains unclear; however, several studies have 
found a benefit of physical exercise as an effective intervention for patients with PD. 
Some research suggests that interventions related to strength training, aerobic training, tai 
chi or dance therapy can result in both short-term and long-term improvement of PD 
symptoms and may have disease modifying effects.5 Dance exercise, particularly Tango 
and Irish dancing, has been shown to be a beneficial therapy for improvement of balance, 
reduction of freezing of gait, and modification of disease in patients with PD.6,7 
 
Statement of the Problem 
Several studies have found that nonmotor symptoms have a greater impact on patient 
quality of life compared to motor symptoms of PD. 8–10 These non-motor symptoms often 
limit patients from working, socializing, and carrying out activities of daily living.11 
Researchers have found that pharmacological treatment of nonmotor symptoms may be 
ineffective or have intolerable side effects that impair balance and cognition, emphasizing 
the need for non-pharmacologic therapies such as dance exercise. Although there has 
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been a great emphasis on reducing the motor symptoms of PD, few studies have 
investigated improvements of nonmotor symptoms as a primary outcome for dance 
exercise interventions. Furthermore, no studies have measured the effect of dance 
exercise on sleep quality in PD patients. 
 
Hypothesis 
PD patients participating in an adapted Tango dance program with daily walking will 
have significant improvement in sleep quality compared to patients who only perform 
daily walking. 
 
Objectives and specific aims 
The purpose of this research is to investigate whether adapted Tango dance exercise can 
be recommended as a valid therapy for patients with PD to improve sleep quality. If the 
findings support the hypothesis that Tango dance exercise has a positive effect on sleep 
quality, providers can improve the quality of life of patients with PD by encouraging 
participation in Adapted Tango Dance Exercise as a weekly regimen. The specific aims 
of this thesis project include the following: 
 To perform a literature review to provide supportive evidence for Tango dance 
intervention and its potential to improve sleep quality and associated depression 
in PD patients. 
 To propose a randomized control trial to investigate the effectiveness of a 6-
month Tango dance intervention on improving sleep quality in patients with PD 
and sleep disturbances. 
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 Within the proposed study, to include a secondary measure of the effect of Tango 
dance exercise on Depression in patients with PD and sleep dysfunction.
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REVIEW OF THE LITERATURE 
Overview: Parkinson’s Disease  
Epidemiology and Etiology 
Currently, over one million patients in the United States are diagnosed with Parkinson’s 
Disease (PD). The prevalence of PD is low in patients under the age of 40 and increases 
to 1% of patients over the age of 60.12 According to the Centers for Disease and Control 
and Prevention (CDC), PD is the second most common neurodegenerative disease after 
Alzheimer’s disease and the complications from PD are the 14th leading cause of death in 
the United States.12 Furthermore, the number of patients with PD is predicted to double in 
the next 15-30 years based on the projected growth of the aging US and world 
population.1 
Pathologically, PD is a progressive neurodegenerative disease characterized by 
depletion of dopaminergic neurons in the substantia nigra, a midbrain structure 
responsible for movement, reward, and addiction, which leads to motor and non-motor 
impairment. The direct cause of cell death and impairment of the dopaminergic neurons 
is still unclear but key determinants include environmental factors, neuroinflammation, 
neurotoxins, genetic factors, and oxidative stress from iron, copper, lipids, and 
proteins.13,14 New pathology research findings suggest that alpha-synuclein is the major 
component of Lewy Bodies, protein aggregations that are suspected to cause idiopathic 
Parkinsonism. 
In terms of the genetic inheritance of the disease, there are currently more than ten 
autosomal dominant or recessive genes or gene loci that have been found to be associated 
 6 
with PD and it is uncommon for patients with PD to have a single gene mutation as a 
cause.15 About 10-15% of patients diagnosed with PD will have first or second-degree 
relatives who are also affected, whereas the remainder of PD patients will have no clear 
inheritance pattern.13 
Clinical Presentation 
Parkinson’s Disease was originally described in 1817 by James Parkinson in his 
monograph “An Essay on the Shaking Palsy”16, claiming that the co-occurrence of 
several symptoms was an indication of a progressive disease, Paralysis agitans, seen in 
several patients. The symptoms he described included involuntary tremulous motion at 
rest, weakness, and a propensity to bend forward while going from a walking to a running 
pace.17  
Two hundred years later, the diagnosis of PD still relies on the clinical 
identification of the cardinal motor features of PD, which include some combination of 
tremor, bradykinesia (slow movement), rigidity, and postural instability. Although 
commonly caused by PD, Parkinsonism is a general manifestation of several 
neurodegenerative disease etiologies including Progressive Vascular Parkinsonism and 
“Parkinson-plus” disorders including supranuclear palsy (PSP), multiple system atrophy 
(MSA), and corticobasal degeneration. These conditions are commonly referred to as 
“atypical parkinsonism” disorders and can be misdiagnosed as PD. A review of 402 cases 
of patients with confirmed Parkinsonism and PD reported over 25% of subjects did not 
benefit from anti-parkinsonian medication, highlighting the difficulty in accurately 
diagnosing PD or offering appropriate and effective treatment.18 
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 The Hoehn and Yahr scale19, first implemented in 1967, is often used to gauge the 
typical patterns of progression of the disease over time. Since its original publication, the 
modified Hoehn and Yahr scale (Table 1) has established more specific half stages and is 
now widely used in clinical practice to define the severity of motor impairment within 
broad stages 1-5. Patients in stages that are greater than Stage 3 have advanced disease 
and severe motor impairment, typically requiring assistance in performing activities of 
daily living (ADLs). 
Table 1 Classification of Parkinson’s disease severity according to the modified Hoehn and Yahr scale (Adapted 
from Hoehn and Yahr, 1967)19 
Stage Signs and Symptoms 
0 No signs or symptoms of the disease 
1 Unilateral involvement only 
1.5 Unilateral and axial involvment 
2 Bilateral involvement without impairment of balance 
2.5 Mild bilateral disease with recovery on pull test 
3 Some postural instability; Mild to moderate disease; Physically 
independent. 
4 Severe disability. But still able to stand or walk unassisted. 
5 Need of a wheel chair or bedridden unless aided. 
 
The Hoehn and Yahr scale is typically supplemented with the Unified Parkinson’s 
Disease Rating scale (UPDRS) which further assesses the limitations of activities of daily 
living and non-motor symptoms.  
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Resting tremor is a characteristic sign of PD, seen in up to 80% of patients with 
PD.20 Resting tremor in PD usually begins unilaterally. Although resting tremor is 
pathognomonic for PD, it is common in other diseases such as multiple system atrophy 
(MSA), supranuclear palsy (PSP), or Lewy Body dementia.21 Early in the disease, PD can 
often be confused for Essential Tremor; however, the presentations have subtle 
differences that make these diseases distinguishable.18  Symmetric tremors are more 
characteristic of Essential Tremor and have a co-occurrence of head and voice tremors. In 
addition, essential tremor is not associated with other cardinal signs, such as rigidity and 
bradykinesia. 
The typical presentation of PD includes bradykinesia, which begins 
asymmetrically in 75% of affected patients.1,21 Patients will often describe a weakness in 
the extremities which may not be appreciated on strength examination. Bradykinesia can 
also be characterized by a reduction in speed and amplitude during repetitive 
performance marked by slow finger tapping, toe tapping, and rhythmic irregularities that 
are seen on physical exam. Small, repetitive movements can be challenging for patients 
and they will often report difficulty with fastening buttons or brushing their teeth. 
Patients with rigidity of PD often describe a stiffness associated with vague 
aching and discomfort of the extremities. Shoulder disturbances, particularly frozen 
shoulder, can present as one of the first symptoms of the disease in at least 8% of 
patients.22 
Postural instability can be observed on gait examination as decreased arm swing, 
presence of foot drag, and slowness of gait. Patients may also notice difficulty rising from 
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a seated position or rolling over in bed. Late in disease progression, freezing, shuffling of 
gait, and falls are disabling for patients those these rarely occur in early stages. 
Non-motor Symptoms of PD 
While PD was traditionally classified as a movement disorder, research and 
evaluation over time have recognized that it is a more complex disease involving 
neuropsychiatric, autonomic, gastrointestinal, and other nonmotor symptoms, in addition 
to the classic motor symptoms. The most prevalent nonmotor symptoms in PD include 
depression, anxiety, sleep disorders, cognitive decline, and fatigue.9 Qin Z. et al and 
Kadastik-Eerme L. et al found that sleep disorders and depression showed the highest 
predictive value for worsened health-related quality of life in patients with PD.8,10 The 
PRIAMO study revealed that 98% of patients with PD suffer from nonmotor symptoms 
and that these symptoms have the most negative impact on quality of life.23 Research 
suggests that these non-motor symptoms are often unrecognized and undertreated by 
clinicians.24,25 In a survey of patients with both early and late stage PD, depression and 
sleep dysfunction were ranked as two of the most troublesome symptoms.26 In addition, 
an international survey in 2008 reported that the majority of patients do not communicate 
symptoms of depression or sleep disturbance to their neurologists during clinical visits.27 
These findings highlight the discrepancy between the perspectives of patients and 
clinicians that can hamper effective management of PD. 
Nonmotor symptoms such as loss of olfactory sensation, constipation, rapid eye 
movement (REM) sleep behavior disorder (RBD), and depression can occur at any stage 
of PD and may present more than ten years prior to the onset of motor symptoms.24,27 In 
 10 
late-stage PD, dementia has been shown to affect up to 80% of patients.28 The clinical 
stage and symptom involvement of PD closely correlates with the progression of Lewy 
Body/alpha-synuclein deposition, as observed by neuropathological studies. Early in the 
disease, Lewy Body deposition in the olfactory bulb and lower medulla first manifests as 
nonmotor symptoms. As the disease progresses, dopaminergic dysfunction and Lewy 
Body deposition in the substantia nigra manifests as motor symptoms. In late-stage 
disease, Lewy Body deposition spreads cranially from the midbrain and into the limbic 
and neocortical regions.29 This, however, should not to be confused with dementia with 
Lewy bodies (DLB), which was recognized in the 1990’s as a distinct dementia syndrome 
associated with a diffuse cortical distribution of Lewy Bodies. DLB is clinically 
characterized by early vivid visual hallucinations, episodic confusion, and atypical 
Parkinsonism. 
The presentation of non-motor symptoms highlights the degenerative involvement 
of multiple areas of the brain beyond the substantia nigra pars compacta.30 As with motor 
symptoms, dopamine plays a major role in regulating nonmotor symptoms. The main 
dopaminergic areas of the brain include the substantia nigra, ventral tegmental area, and 
hypothalamus. These areas have axons that extend to form four main dopaminergic 
pathways: the nigrostriatal, mesocortical, mesolimbic, and tuberoinfundibular pathways 
respectively which regulate non-motor functions such as cognition, sleep, and pain.24 
Further evidence of non-motor dopaminergic involvement was demonstrated by a PET 
study performed in 2008 that correlated symptoms of sleep disorders, autonomic 
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dysfunction, and other neuroendocrine abnormalities to dopamine dysfunction in the 
hypothalamus.31 
Sleep Dysfunction 
Sleep disorders, including insomnia, daytime sleepiness, restless leg syndrome (RLS), 
and RBD, affect an estimated 55-80% of patients with PD.2 In an international survey of 
242 patients with PD, daytime sleepiness, and intense and vivid dreams were the most 
common undeclared and untreated symptoms.27 In general, sleep disorders are a 
consequence of extrapyramidal system impairment, leading to dysfunction of arousal 
mechanisms.32 Dopamine has been found to play a complex role in regulating the sleep-
wake cycle and the susceptibility of dopaminergic neurons in PD may be associated with 
sleep disorders in affected patients. Structures such as the substantia nigra are also linked 
to REM and non-REM sleep circuits.  
Common sleep disorders seen in PD include sleep-onset insomnia (difficulty 
falling asleep) and sleep-maintenance insomnia (difficulty remaining sleep). While sleep-
onset insomnia may be intrinsic to the disease pathophysiology, sleep-maintenance 
insomnia can be attributed to a range of associated symptoms, such as nocturnal muscle 
rigidity, nocturia, RLS, periodic limb movements of sleep (slow rhythmic flexion of the 
extremities), and RBD.33 
PD patients often report RLS symptoms, characterized by an unpleasant and 
uncomfortable urge to move the legs during periods of inactivity. RLS may often be 
confused with other symptoms of PD such as wearing-off symptoms, akathisia, or 
internal tremor, making the prevalence of RLS in PD difficult to assess. In addition, 
periodic limb movements of sleep and akathisia commonly overlap with symptoms of 
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RLS, further contributing to sleep disturbance in patients with PD.34 The data for 
prevalence of RLS in PD is inconsistent. However, some studies report that the 
prevalence of RLS is higher in patients with PD than with other parkinsonian 
syndromes.35 Several studies report a two-fold increase in the prevalence of RLS in 
patients with PD compared to the general population.36,37 When compared to idiopathic 
RLS, patients with PD associated RLS were less likely to have a positive family history 
of RLS and typically present with PD symptoms before the onset of RLS symptoms. 
Secondary risk factors such as low ferritin levels and impaired iron acquisition are 
associated with RLS in patients with PD.37 While both RLS (idiopathic and PD-
associated) and Parkinson’s disease respond to dopaminergic therapy, some data suggests 
their etiology is separate and distinct. Several imaging and neuropathologic studies 
demonstrate that RLS involves changes in mesocortical dopamine pathways and, unlike 
PD, mild dysfunction of the striatal pathway.38 
Rapid eye movement (REM) sleep behavior disorder (RBD), first described by 
Schenck et al in 1986, is a parasomnia characterized by vivid and usually frightening 
dreams or nightmares that occur during REM sleep. During this period, the patient will 
often exhibit an absence of muscle atonia and paradoxical simple or complex movement 
associated with the nightmares. These movements may range from muscle twitching to 
violent axial movement or bed falls, which are a risk to the patient and bed partners. RBD 
has been strongly associated with neurodegenerative disease and is present in up to 60% 
of patients with PD.39 Symptoms of RBD can precede the diagnosis of PD by an average 
of 13 years. Between the time RBD is first reported and the diagnosis of PD, there may 
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be a latent period without neurological signs or symptoms.40 In patients without signs of 
parkinsonism, Postuma et al41 found an estimated 18% five-year risk and 41% ten-year 
risk for Parkinsonism after RBD was diagnosed. Although the etiology and pathology of 
RBD is virtually unknown, this disease has been found to be associated with degeneration 
of the pedunculopontine and peri-ceruleal nucleus, lower brainstem nuclei with 
connections to the dopaminergic ventral tegmental area in the midbrain. The 
pathophysiology of RBD involves the degeneration of the sublaterodorsal nucleus and its 
projections to the spinal interneurons.42 
Depression 
 Clinical characteristics, such as anhedonia, loss of appetite, feelings of hopelessness, 
difficulty sleeping and cognitive deficits, are common manifestations of depression. 
Depression is the most common neuropsychiatric disorder in PD and has been reported to 
affect up to 45-50% of patients.4 Although the reason for the high prevalence of 
depression in PD is unclear, research shows that the etiology involves the dysfunction of 
dopaminergic, serotoninergic, and norepinephrinergic pathways in the limbic system. In 
vivo imaging studies have detected a loss of dopamine and noradrenaline innervation in 
the locus coeruleus and the limbic system in patients with PD and depression compared 
with non-depressed patients with PD.43 The severity of depression and concomitant 
anxiety showed an inverse correlation with the binding of dopamine and noradrenaline in 
the patients studied. Recognition of depression in PD remains a challenge for clinicians 
because it can resemble Bradykinesia, masked facies (loss of facial expression), cognitive 
dysfunction and sleep disturbance seen in patients without depression. 
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Diagnosis of PD 
Post-mortem pathologic evaluation has shown cytoplasmic inclusions, known as Lewy 
Bodies, within residual dopaminergic neurons; however, their functional significance is 
unknown. Because of the lack of pre-mortem biological markers, the diagnosis of PD is 
based on clinical evaluation with reliance on patient history and physical examination. 
Sometimes additional tests, such as Magnetic Resonance Imaging (MRI), are utilized to 
rule out other conditions when a patient has prominent gait abnormalities but is 
unnecessary in typical presentations.  
Patients without a firm diagnosis of PD may undergo a challenge trial of levodopa 
or apomorphine to assess for pharmacologic response.44 Atypical parkinsonsism patients 
will not respond to pharmacologic therapy with levodopa and tend to have a worse 
prognosis than patients with idiopathic PD. Patients with atypical parkinsonism can be 
clinically differentiated from PD when the symptomatology includes atypical signs, such 
as symmetric tremor, intention tremor, early presentations of cognitive impairment or 
mechanical falls, wide-based gait, or rapid progression of disability within five years of 
onset. Marked orthostatic hypotension, abnormal eye movements, and Babinski signs are 
also inconsistent with the diagnosis of PD and tend to be manifestations of atypical 
parkinsonism or Parkinson-plus syndromes. 
The absence of identifiable biologic markers creates a challenge when trying to 
distinguish PD from other movement disorders with similar clinical presentations early in 
the disease course and which also lack early disease markers. An erroneous diagnosis of 
PD is often revealed only after these patients come to autopsy. One clinico-pathological 
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study found 24 of 100 cases that had a diagnosis of PD in life were erroneously 
diagnosed, showing evidence of non-PD etiology of Parkinsonism on autopsy. The 
diagnoses in these autopsy samples were predominantly reclassified as progressive 
supranuclear palsy (PSP), multiple system atrophy (MSA), Alzheimer's disease, and basal 
ganglia vascular disease.45 Furthermore, other research findings highlight a high rate of 
undiagnosed PD, ranging from 12-60%.46 However, these numbers are likely an 
overestimation of misdiagnosed PD, resulting from a referral bias as patients with a 
questionable diagnosis are more likely to be referred for autopsies. Nevertheless, these 
findings address the limitations of the clinical diagnosis of PD in the general population 
based on published criteria. 
In clinical practice, patients with PD need to be distinguished from reversible 
causes, such as drug-induced parkinsonism. In a population study, drug-induced 
parkinsonism was found to be the cause in 20% of parkinsonism cases. The most 
prominent drugs known to have parkinsonism side-effects include neuroleptics, dopamine 
antagonists, calcium channel blockers, and anti-emetics. Some pharmacologic agents, 
particularly dopamine antagonists, are known to exacerbate PD and should be avoided in 
these patients. 
Treatment of PD 
PD is known as a progressive disease, however, the rate of progression and symptom 
presentation varies from patient to patient and population to population. As such, 
symptom severity and patient preference determines the approach to treatment. Currently, 
there is no curative therapy for PD and treatment relies on symptom management. 
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Treatment of PD is divided into pharmacologic, surgical, and nonpharmacologic/ 
nonsurgical therapy.  
Pharmacologic therapy 
Pharmacologic therapy for managing motor symptoms includes levodopa, dopamine 
agonists (DA’s), anticholinergic agents, monoamine oxidase (MAO-B) inhibitors, 
Catechol-O-methyl transferase (COMT) inhibitors, and amantadine. Patients with milder 
symptoms early on in the disease do not necessarily require drug therapy. Initiation of 
pharmacologic treatment is indicated for patients whose symptoms affect their daily life 
or who have significant disability. 
Levodopa 
Levodopa when combined with a peripheral decarboxylase inhibitor is known to have the 
most benefit for reducing symptoms of PD, especially bradykinesia, tremor, and 
rigidity.47 Levodopa is less effective for postural stability and coordination. Because of 
adverse side effects and concern for toxicity, levodopa is generally reserved for patients 
older than 65 whose motor symptoms have become disabling or have an inadequate 
response to a DA at maximal tolerated dose.48 It is required in high dosage because of the 
rapid inactivation of levodopa by decarboxylation and competition with other amino 
acids in the gut lining. Carbidopa, a decarboxylase inhibitor, is typically combined with 
levodopa to help with absorption and prevent nausea, vomiting, and orthostatic 
hypotension. The dosing varies for each patient, depending on the severity and 
progression of PD symptoms. For refractory disease, a gastrojejunostomy tube may 
percutaneously deliver a continuous dose of levodopa-carbidopa (Duopa) with an 
intestinal gel infusion. 
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Common side effects for patients receiving high levels of levodopa include 
dyskinesia, nausea, somnolence, confusion and headache compared to placebo. 
Additionally, some neuroimaging data suggest that levodopa accelerates the loss of 
nigrostriatal dopamine terminals, but that could alternatively be a reflection of 
pharmacologic down-regulation of dopamine transporters.49 
Dopamine Agonists (DA’s) 
DA’s primarily act on D2 –like dopamine receptors and include ropinirole, pramipexole, 
rotigotine, and apomorphine.50 Dopamine agonists can be prescribed as a monotherapy or 
combined with other antiparkinsonian medications. Initiation of a DA is appropriate for 
young-onset PD in those under 65 years-old with cognitive abilities intact. Compared to 
levodopa, DA’s have a lower risk of motor fluctuations and dyskinesia. Although DA’s 
can initially delay treatment with levodopa, most patients are poorly maintained on DA 
monotherapy after the first five years of treatment and may be at risk for impulse control 
behaviors. It can be administered as a subcutaneous injection, known as Apomorphine, 
that may be used as a rescue therapy or continuous infusion to treat levodopa-related 
motor fluctuations or “off” episodes. Of the few studies comparing DA agents, most have 
shown no significant difference in efficacy.51,52  
DA’s have similar adverse effects to levodopa but have been shown to be 
significantly more likely to cause nausea, edema, somnolence, orthostatic hypotension, 
confusion, and hallucinations.53 In a survey54 assessing daytime sleepiness with DA use, 
23% of patients reported “sleep attacks” while driving, increased incidence of motor 
vehicle accidents, and sleep disorders such as RLS. 
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Anticholinergics 
Anticholinergics were the first drugs used for treatment of PD symptoms and continue to 
be used as a monotherapy or as part of combined regimens. Dopamine dysfunction causes 
a cholinergic sensitivity that can exacerbate PD symptoms.55 Anticholinergic agents, such 
as trihexyphenidyl, are widely used for patients under the age of 70 with disturbing 
tremor but without significant bradykinesia or gait disturbance. These agents have some 
effect for patients with levodopa or DA resistant tremors. Psychiatric side effects of 
anticholinergics have been long recognized as the major limiting factor for their use and 
should be avoided in patients who are older, patients with dementia, and who do not 
present with tremor.56 Adverse effects in susceptible patients include confusion memory 
impairment, hallucinations, nausea and peripheral antimuscarinic side effects. 
Monoamine oxidase B (MAO-B) inhibitors 
MAO-B inhibitors, such as selegiline, rasagiline, and safinamide, are used as a 
neuroprotective therapy for patients with early-stage PD but have limited symptomatic 
benefit as a monotherapy. Some evidence suggests that MAO-B inhibitors may delay the 
initiation of levodopa therapy and is sometimes used as an adjuvant.57 Nausea and 
headache are associated side effects of MAO-B inhibitors. The use of Selegiline is 
limited to early-onset PD as it often causes confusion in older adults. 
Catechol-O-methyl transferase (COMT) inhibitors 
COMT inhibitors, such as entacapone or tolcapone, are used in combination with 
Levodopa to potentiate or prolong its antiparkinsonian effect, particularly in patients with 
fluctuating motor symptoms. COMT inhibitors often require lower doses of levodopa by 
up to 30% in order to avoid dyskinesia..47 Tolcapone has been associated with 
hepatotoxicity so transaminases must be closely monitored within the first six months of 
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initiating therapy. Common side effects, including dyskinesia, visual hallucinations, 
nausea, diarrhea, and orthostatic hypotension, are related to increased dopaminergic 
stimulation. 
Best used as a short-term monotherapy, amantadine is an antiviral agent that has 
mild antiparkinsonian effects. It is primarily used in treating levodopa induced 
dyskinesias. Toxicity is low and more likely to affect older patients in combination with 
other antiparkinsonian drugs. 
Treatment of Sleep Dysfunction 
Treatment of RLS and periodic limb movements are poorly defined. However, 
pharmacologic studies have demonstrated the effectiveness of levodopa, dopamine 
agonists, benzodiazepines, opioids, clonidine and carbamazepine.34 PD and RLS both 
respond to dopaminergic therapy, despite studies that show distinct pathophysiologies.37 
Because the etiology remains unclear, the treatment of these sleep disturbances generally 
focuses on symptom management.  
Both melatonin and clonazepam are both effective in treating RBD in the majority of 
patients.58 However, clonazepam has known side effects including daytime sleepiness, 
confusion, cognitive impairment, and poor coordination. Because of its favorable side 
effect profile, melatonin is the preferred initial therapy for RBD. 
Treatment of Depression 
Although there is no consensus for the most effective treatment of depression in patients 
with PD, selective serotonin reuptake inhibitors (SSRI’s) are the most commonly used 
therapy based on its favorable side effect profile.59 Antidepressants that have the most 
evidence for effective treatment of depression with PD include citalopram, sertraline, 
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paroxetine, fluoxetine, venlafaxine, amitriptyline, nortriptyline, and desipramine. A 
randomized control trial, the ADAGIO study60, demonstrated the effectiveness of 
monoamine oxidase B (MAO-B) inhibitors in reducing worsening depression symptoms 
when combined with an antidepressant. 
Surgical Therapy 
Surgical therapy is known to have the most benefit for patients with motor fluctuations or 
poorly controlled motor symptoms on medication alone. Deep-brain stimulation (DBS) of 
the STN and globus pallidus interna (GPi) affects the dopaminergic modulation in the 
nigrostriatal pathway. DBS involves stereotactic brain surgery for electrode and pulse 
generator implantation to alleviate motor fluctuation and dyskinesia.61 Risks include 
infection, hemorrhage, and mechanical disruption. 
Exercise therapy 
Broad-based management of PD includes nonpharmacologic/ nonsurgical therapy, such 
as patient and family education, support groups, regular exercise, physical activity, and 
speech therapy. Evidence has suggested that exercise may improve functional outcomes 
and alleviate joint and back pain associated with rigidity and flexed posture.62 Aerobic 
exercise has been associated with greater improvement in PD symptoms compared to 
strength, resistance, and stretching exercises.63 A randomized controlled trial64 of 195 
patients with mild to moderate PD showed significantly less self-reported falls after six 
months of Tai Chi when compared to the resistance training and stretching groups. 
Some research has suggested the possibility that, because patients with PD have 
lower levels of dopamine at baseline, they are more susceptible to the benefits of physical 
activity than patients without PD.65 Hence, the increase of dopaminergic activity from 
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exercise has a targeted biologic effect in patients with PD. Other studies have shown 
improvement of sleep quality likely related to perturbations of several neurotransmitters 
systems, including norepinephrine and serotonin that are afferent to the hippocampus.31,66 
Furthermore, parkinsonian animal models have demonstrated a neuroprotective effect 
from dopaminergic neurotoxins mediated by brain-derived neurotrophic factor (BDNF), a 
protein that increases during exercise in humans.65 Although exercise may not slow the 
progression or eliminate PD symptoms, such as akinesia, rigidity, or gait disturbance, it 
has been associated with improvement in the patient’s physical and mental state that can 
affect overall quality of life in patients with PD. 
  
Existing research 
As discussed in “Non-motor symptoms”, patients with PD have a high frequency of sleep 
disorders and other non-motor symptoms, such as depression, that are unrecognized, 
untreated, and unimproved by antiparkinsonian pharmacotherapy. A community-based 
study of 245 patients with PD demonstrated that the frequency of sleep disorders and 
depression correlated with the duration of levodopa treatment in patients with PD.2 This 
underlines the importance of identifying and treating these conditions as part of effective 
management, while minimizing drug therapy through the use of nonpharmacologic 
interventions, such as regular exercise. Despite the high frequency of sleep disorders and 
depression and their significant impact on quality of life, most exercise and dance-related 
research tends to focus on motor symptoms in PD rather than non-motor symptoms. 
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Long-term adherence to exercise regimens can be challenging for patients, 
especially elderly patients with progressive neurological impairment. However, physical 
activities that are engaging and enjoyable, such as dancing, may enhance adherence over 
a longer term. When compared with other forms of exercise, dance practice induces 
better responses in motor symptoms and functional mobility in PD patients than in 
physical therapy or self-directed or other traditional exercises.67 These functional benefits 
can lead to improvement in autonomy, independence, and fall-prevention. In terms of 
non-motor symptoms, the involvement of musical stimuli in dance exercise has been 
shown to increase reward system signals by activating a release of dopamine in the 
ventral tegmental region, leading to improvement of mood and cognition of patients.68  
Much existing evidence supports the benefits of exercise on sleep quality in the 
general population with some observing that elderly physically fit men have shorter sleep 
onset latency, reduced wake time after sleep onset, higher sleep efficiency and greater 
total slow-wave sleep compared to elderly sedentary men.69 However, only a few studies 
have investigated the effects of exercise on sleep quality in patients with PD. Most of the 
data for sleep quality in these studies were collected via a subjective rating system. One 
randomized controlled trial performed by Nascimento et al70 evaluated the change of 
sleep quality in 42 patients with PD and Alzheimer’s Disease.They used a Mini-Sleep 
Questionnaire to measure sleep quality before and after a six-month multimodal exercise 
intervention that included resistance, aerobic and balance training. Their findings showed 
an improvement of sleep quality in the group given the intervention relative to the control 
group who did not participate in exercise training. In a 3-year intervention study, 
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Modugno et al. compared active theatre to physical therapy in a small group of PD 
patients and found that patients who practiced theatre acting showed an improvement in 
daytime sleepiness, depression, quality of life, and ADLs compared to physical therapy 
patients.71 Qigong is a variant of Tai Chi with a focus on meditation and slow 
movements. Several studies have shown that Qigong may improve sleep quality and 
quality of life in PD patients. A recent study by Xiao and Zhuang found a greater 
improvement of sleep in PD patients randomized to Qigong plus walking compared to 
walking alone using the PD sleep scale (PDSS-2). Currently, there are no studies that 
have measured the effects of dance intervention on sleep disturbance in adults with PD.72 
While there are no studies measuring sleep quality response to dance intervention, 
previous research has been performed on evaluating other related non-motor symptoms, 
such as health-related quality of life and mood. Depression, the most common 
psychological symptom related to poor quality of life in patients with PD, has been 
shown to improve with regular exercise and dance; however, the mechanism by which 
this occurs remains unclear. Psychosocial benefits of dance exercise have been implicated 
though; studies have shown an improvement of depression symptoms when the exercise 
involves social interaction with trainers and other participants.73 A randomized controlled 
trial of older patients above the age of 60 showed that ballroom dancing reduced 
depressive symptoms in nursing home residents.74 This study included patients with or 
without PD who were randomly assigned to participate in ballroom dance exercise once a 
week for 60 minutes over the course of 3 months. The dance group had significantly 
improved depressive symptoms, whereas the control group (no dance intervention) 
 24 
experienced worsening of depression. Lee et al75 studied the depression-alleviating 
effects of virtual dance in PD patients within a six-week period. The virtual dance 
method incorporated repetitive melodies, simple rhythms, and moves that were highly 
attractive and amusing to PD patients. The findings included higher values for balance, 
activities of daily living, and depressive disorder status in the experimental group who 
received dance exercise compared with the control group with no exercise. Conversely, 
there was no significant difference in depression in a randomized study of PD patients 
enrolled in a 12-week Argentine tango program compared with a self-directed exercise 
group68. However, this study included PD patients both with and without depression. 
Thus, there may not be any added benefit in mood in PD patients without depression. 
 The effects of dance intervention have shown an overall benefit to motor 
symptoms and quality of life. Compared to other forms of dancing, however, Tango may 
have more targeted benefits for symptoms associated with PD.76 Only one study, 
performed by Hackney M. and Earhart G., compared the effects of different dance 
interventions on motor and some non-motor symptoms in PD and found greater 
improvements with Tango compared to other ballroom dance interventions.76 
Furthermore, patients who reported greater problems in social support had higher 
depression, anxiety and stress levels that were only improved in the Tango arm. In their 
pilot study, they also compared the effects of Tango, Waltz/Foxtrot, Tai Chi and No 
Intervention on health-related quality of life in PD patients. After 20-weeks of 
participation, Tango was the only intervention that showed significant improvement in 
quality of life compared to Waltz/Foxtrot, Tai Chi or No Intervention.77 A study by 
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Duncan et al. comparing a one-year Tango program to no intervention found 
improvements in motor function testing while off medication, suggesting that 
participation in the Tango program may have a disease modifying effect in PD. Some 
improvement in non-motor symptoms and ADLs were observed, although these results 
were not significant, possibly due to the large variability in scores between participants.78 
The evaluation used only has one question aimed at evaluating sleep problems, 
warranting additional sleep-targeted testing in future studies. 
Sleep and depression constitute a small component of the generalized assessments 
used to measure general health related quality of life in these previous studies. As far as 
we know, no dance intervention studies have studied sleep as a primary outcome in PD 
patients. Although several studies have found that Tango-style dancing targets motor and 
non-motor symptoms of PD, this randomized controlled trial will be the first Tango 
intervention study to measure sleep quality directly in patients with PD.  
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METHODS 
Study design 
The proposed study will be a randomized controlled trial comparing sleep quality in two 
treatment arms, a dance intervention with walking and walking alone. This design is 
based on the randomized controlled trial by Xiao et al., the only exercise intervention 
study that measured sleep quality in PD as a primary outcome. 
 
Study population and sampling 
Inclusion Criteria 
This study will include all genders and patients between the ages of 55–80 years. Patients 
must be on a stable regimen of PD for at least 2 weeks prior to enrollment and must 
remain on this regimen until the final evaluation for the study. This will maintain 
pharmacologic therapy as a constant variable in order to attribute PDSS-2 score changes 
to dance intervention directly. Participants of this study must score 1-3 on the modified 
Hoehn & Yahr PD rating scale19 with a diagnosis of PD by a medical practitioner. This 
criteria includes patients who have mild to moderate PD and are physically capable of 
performing Tango exercises. To maximize safety, the patient sample will include patients 
who are able to walk independently with postural reflexes intact. In order to participate in 
instructional dance exercise patients will be required to take the Mini Mental-Status 
Exam (MMSE) and obtain a score >23, ensuring that they are able to follow simple 
commands and do not have signs or a diagnosis of dementia. Participants must be able to 
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travel to the dancing venues (senior living facility) by a caretaker, family member, or any 
other safe method. 
Exclusion Criteria 
Patients with a history of unstable/uncontrolled medical conditions, including 
neurological, cardiovascular or orthopedic diseases affecting postural stability will be 
excluded from the study. CVD associated with cardiac sympathetic denervation has been 
associated with early fatigue and may have adverse effects on the motivation of patients 
to perform the dance exercises that are aerobic in nature. Patients will be excluded if they 
have on–off motor fluctuations and dyskinesia above grade 3 on the Unified Parkinson’s 
Disease Rating Scale (UPDRS). In addition, we will exclude patients who have other 
uncontrolled comorbid conditions affecting sleep, such as obstructive sleep apnea 
requiring ventilation, or if patients are prescribed sleep-affecting medications, such as 
antipsychotics, antidepressants, or benzodiazepines. This study will exclude patients with 
a current or recent history of practicing dance. Patients will not be excluded based on 
gender or ethnicity.  
The study will require a sample size of 90 patients with 45 patients per arm to 
detect a significant difference by the student’s t test in improvement of sleep quality, as 
measured by the PDSS-2 scale. This is calculated from an alpha of 0.05, a power of 80%, 
and an effect size of 6.7 and a standard deviation 11.18. These numbers were generated 
based on the results from Xiao and Zhuang. We predict that our intervention method will 
yield similar or superior results in sleep quality improvement. In contrast to Qigong, 
partnered dancing will allow greater social interaction and musical stimuli which have the 
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potential for increased benefits in nonmotor symptoms of PD. However, the Qigong 
patients were given audiovisual instruction to allow for practice four or more days per 
week, whereas our participants may or may not have access to video-recorded instruction 
possibly masking the superiority of the dance intervention compared to Qigong. 
 
Intervention 
The intervention of this study will be participation in a Tango dancing program. This 
intervention was chosen based on the study performed by Hackney M. and Earhart G., 
which showed Tango patients had greater improvements in quality of life compared to 
Waltz/Foxtrot, Tai Chi or No Intervention patients.79,80 The length of class will be 60 
minutes, the frequency of classes will be 3 times per week, and the duration of the 
program will be 6 months to yield comparable results to Xiao et al (at least 45 min., 4 
days weekly for 6 months). In order to eliminate confounding factors related to baseline 
physical fitness, all patients who participate in this study will be asked to maintain a daily 
exercise routine of at least 30 minutes of walking. Both groups must document all 
sessions of exercise in a time log diary provided to them. In addition to the tango dance 
instructor, every Tango session will have at least one physical education professional 
who is familiar with PD and trained in the physical rehabilitation process of chronic 
pathologies. Each class will also have 1-2 young volunteers to assist with safety 
monitoring, exercise guidance, and fall prevention. Family members, friends and 
volunteers will be encouraged to participate, partner and assist PD participants in all 
Tango intervention sessions. The classes will be offered at Senior Living Facilities that 
would agree to hold classes for our patients. 
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Study variables and measures  
The independent variable of this study will be participation in Tango classes or not. The 
primary dependent variable in this study will be Sleep Quality as measured by the PDSS-
2 (see Appendix 1), a 15-item questionnaire that surveys sleep issues related to Motor 
Symptoms at Night, PD Symptoms at Night and Disturbed Sleep. The maximum 
cumulative score for the PDSS-2 is 60, which reflects no symptoms. Depression will be 
measured as a secondary outcome by using the Beck Depression Inventory-II (BDI-II, 
see Appendix 2), with higher values (score 0-63) indicating greater depression. 
 
Recruitment 
Patients will be recruited from the Boston Medical Center (BMC) database of patients 
who have a diagnosis of PD by a medical practitioner, have been evaluated and followed 
by a neurologist at BMC, and who report poorly controlled sleep disruptions. During 
their next follow-up visit with the neurologist, patients will be asked to participate in the 
study and given a written consent form, the PDSS-2, and BDI-II. All participants must 
provide written informed consent before participation in the study. The week prior to the 
start of classes, the patients who have signed the consent will be re-evaluated for baseline 
PDSS-2 and BDI-II scores. Those who are randomly assigned in the Tango group will be 
given a pamphlet, and both groups will receive instructions regarding daily time logging 
and weekly emails for class schedule/walking exercise reminders. 
 30 
Data collection 
The primary outcome of sleep quality will be measured by the PDSS-2 and the secondary 
outcome of depression will be measured by the BDI-II. This study will use the same test 
(PDSS-2) to evaluate patients as that used by Xiao et al. in order to provide comparable 
results between the Tango and Qigong interventions. 
Participants will first be asked to undergo an initial evaluation the week prior to 
the start of their first Tango class in order to assess baseline sleep quality, using PDSS-2, 
and depression, using BDI. Data on co-variables and confounders will be obtained and 
screened for by using the BMC database. Additionally, tests such as the Hoehn & Yahr 
for PD disease staging,  MMSE for mental status, and UPDRS for motor symptom 
fluctuations, dyskinesia, and other confounding factors will be assessed in order to 
determine if patients meet the inclusion criteria. For PDSS-2 and BDI-II outcome 
measures, all PD patients will be evaluated on the “off” phase (12 hours without taking  
PD medications). Attendance at each class will be recorded, and patients will be required 
to record sign-in and sign-out time. The classes will be video recorded to document any 
incidence of falls. In addition, patients will be asked to time log sessions of exercise, 
including Tango classes, any additional Tango practice outside of class, and daily 
walking. Participants will be evaluated at BMC by a neurologist the week following the 
last class of the 6-month Tango program to record PDSS-2 and BDI-II follow-up scores. 
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Data analysis 
Once the PDSS-2 and BDI-II scores (assumed to be normally distributed) are recorded 
pre-intervention and post-intervention for each participant, the difference of each score 
will be calculated. To ensure patients in both the Tango group and control group have no 
significant differences in demographics and pre-intervention PDSS-2 and BDI-II scores, 
the chi-squared test will be used to compare categorical variables and the student’s t-test 
will be used to compare continuous variables. The change in sleep quality will be defined 
as the difference between the pre-intervention scores and post-intervention scores. The 
mean of the change in sleep quality between the two groups will be compared using the 
student’s t-test. Pre-intervention PDSS-2 means should show no significant difference 
between the experimental and control groups. The magnitude of improvement in sleep 
score due to the intervention will be adjusted for potential confounders using Multivariate 
linear regression. P-values of <0.05 will be considered significant. 
 Tango group adherence will be defined as attending greater than 75% of classes 
and the proportion adherent will be reported. Additionally, the change in sleep quality of 
adherent participants will be compared to non-adherent and controlled participants by 
ANOVA. If there is a significant difference, pairwise t-tests will be used to compare each 
group, adjusting the alpha-level using the Bonferroni correction to reduce the likelihood 
of commiting an alpha error. 
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Timeline and resources 
At the start of August 2018, one month prior to recruitment, an application for full board 
review will be submitted to the Institutional Review Board at Boston University. 
Recruitment of staff would require a total of 2-3 months and should be initiated near the 
beginning of September 2018. The Principal Investigator and co-investigators will be 
neurologists, residents, physician assistants, or nurse practitioners affiliated with the 
BMC neurology department. A part-time study coordinator with at least one year of 
clinical research experience will be recruited from Boston University Medical Campus or 
BMC students, faculty, or medical staff who would be responsible for subject 
recruitment, patient consent, data entry, and documentation. Flyers, emails, and online 
announcements will be distributed in order to recruit these key study personnel. 
Approximately 5-10 instructor trainees from an available population of therapists, 
professional dance and fitness instructors will be recruited from within the Boston area. 
We will verify that instructors have at least 2 years of experience teaching dance, a clear 
understanding of movement principles, and verify past experience working with older 
and disabled patient populations. Training will be based on the Adapted Tango Manual 
which delineates all aspects of adapted tango and will be made available for reference in 
planning classes. The Adapted Tango Teacher training program79 will be described to 
instructors and implemented as a 12-hour workshop with 3-hours of individual 
instruction to ensure a full understanding of principles, techniques, and safety protocols. 
The adapted syllabus81 for the tango program includes lesson plans that describe the 
rhythms and steps of the day. All recruited staff will be encouraged to attend the 
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American Congress of Rehabilitation Medicine Conference OCT 25-28 2018 for an 
instructional course presented by Dr. Madeleine E. Hackney, the founder of the Adapted 
Tango Dancing Program for PD patients. Otherwise, a request will be sent to Dr. 
Hackney to host an instructional orientation in Boston planned for November 2018. 
Teacher training would require approximately one month and should be completed by 
mid-December 2018. 
Young volunteers will be recruited from physical therapy, pre-physical therapy 
and pre-medical programs at Boston University, and will be educated about monitoring 
for postural and gait instability associated with PD and safe assistance techniques to 
prevent falls. 
The intervention will require approval from a senior living community (SLC) in 
Boston who will agree to host Tango classes. Approval from the SLC administrators will 
be obtained with letters of support stating an incentive to offer the classes free of charge 
to all residents within their community. Weekly communication with SLC administrators, 
staff, instructors, and class coordinators will be maintained for feedback. 
Patient recruitment should be completed by March 2019 in order to initiate classes 
in the spring and avoid weather-related transportation issues. Classes and patient 
evaluation will require a total of 26 weeks, with the last class ending in September 2019. 
Data collection and statistical analysis will require an additional 1-2 months from the end 
of classes. Depending on classroom availability and scheduling of patients, this study 
should require a total of 15 months from the start of staff recruitment, assuming teacher 
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trainees and patients start classes at the same time. The anticipated completion and 
publication date of this study will be November 2019. 
 
Institutional Review Board 
This study involves recruitment and participation of human subjects that will require a 
full-board review from The Boston University Medical Center Institutional Review 
Board. This study will obtain IRB approval before the initiation of recruitment and study 
performance.  
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CONCLUSION 
Discussion 
Tango has been associated with superior outcomes for improving PD motor and 
nonmotor symptoms compared to other interventions or no intervention. This study will 
be the first to measure sleep quality improvement as a primary outcome with this 
intervention, though. Methods of this study are based on the only known exercise 
intervention study that measured sleep quality as a primary outcome and found 
significant improvement in PDSS-2 scores, a scale for sleep quality, after a 6-month 
Qigong (a Tai Chi variant) program. Previous studies have demonstrated a greater 
improvement in quality of life in Tango compared to Tai Chi and no intervention. Based 
on these findings, we predict there will be significant improvement in sleep quality with 
our Tango intervention and walking compared to walking alone. Because of the strong 
association between sleep and depression, we predict there will also be a significant 
improvement of depression in the Tango intervention group compared to the control 
group. 
One of the potential limitations of this study, as with any exercise intervention 
trial, will be patient compliance and attrition rates. Transportation to the site may create 
some difficulty for patients to attend all classes. In this targeted population, poor sleep 
quality and depression can decrease motivation to participate and may decrease exercise 
endurance. Because these classes will be offered free of charge and in an enjoyable social 
setting, these limitations may be minimized compared to other exercise intervention 
methods. 
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Tango provides PD patients an increased benefit over other exercise interventions 
because it targets various complications that are specific to the disease. Patients with PD 
may benefit from Tango intervention because it involves backward walking, step 
coordination, and synchronized rhythm with elements of musical therapy While these 
elements of tango have been shown to improve motor function and quality of life, their 
benefits may also extend to improve non-motor symptoms that have not yet been 
measured as primary outcomes in previous studies.  In addition, Tango requires patients 
to engage in a social environment and build positive relationships that are important for 
motor and nonmotor symptom outcomes in PD. Furthermore, depression and anxiety 
symptoms have also been associated with decreased dopamine transporter activity in the 
anterior putamen, an area that Tango has been shown to activate.82 Prior studies have 
found a high satisfaction rate among PD patients who engage in Tango. Thus, Tango 
dance programs may yield a higher compliance rate and long-term adherence as it may be 
a more enjoyable form of exercise compared to physical therapy, self-directed exercise, 
or other standardized forms of physical activity. 
The PDSS-2, used to measure the primary outcome of this study, is an objective 
assessment that determines the severity of sleep disturbance by identifying individual 
symptoms and allowing for a targeted approach to treatment of nocturnal symptoms in 
PD. Strengths of this method are that it offers a simple, clinical, and cost-effective 
bedside tool for semiquantitative evaluation of sleep quality in PD patients. In addition, 
the test is available in four languages allowing it to be used widely in diverse patient 
populations such as those seen at Boston Medical Center (BMC). A limitations of using 
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the PDSS is that it cannot be validated against a gold standard measurement of sleep 
architecture, such as polysomnography.83 The PDSS-2 is a superior metric of sleep 
quality in PD patients compared to other scales as the UPDRS has one question related to 
sleep, and the quality of life scale (PDQ39) has limited evaluation of sleep, as well. The 
PDSS-2 systematically addresses the specific nature of sleep dysfunctions in PD and 
quantifies the severity and frequency of sleep disturbances, whereas the Epworth 
Sleepiness Scale, UPDRS and PDQ-39 do not. 
Because of the wide variation in study designs and methods, the optimal intensity, 
frequency, and duration of dance interventions for patients with PD or the general 
population cannot be determined from existing research. Direct comparisons of 
interventions of different intensities, durations, and dance types are necessary to develop 
recommendations. Extensive literature review reveals a need for future studies to analyze 
the effects of standardized dance programs in patients diagnosed with PD. 
 
Summary 
Traditionally, PD is considered a movement disorder for which the clinical diagnosis and 
treatment are focused on motor symptoms. Despite there being a clear association 
between quality of life and non-motor symptoms, such as sleep dysfunction and 
depression, most existing exercise research focuses on motor symptoms. Surveys of PD 
patient populations have revealed the high frequency of sleep dysfunction and depression 
that are left unrecognized and untreated, yet PD patients rank depression and sleep 
dysfunction as having the highest impact on quality of life. Non-pharmacologic regimens 
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such as regular exercise may minimize symptoms of depression and duration of levodopa 
treatment, both having significant associations with sleep dysfunction.2. Dance exercise 
may improve adherence to exercise regimens as it involves social relationships that are 
important for quality of life. In addition, the involvement of musical stimuli during dance 
may be a targeted therapy for PD symptoms by activating a release of dopamine in the 
ventral tegmental region, leading to improvement of mood and cognition of patients.68 
Tango style dancing may have added benefits to PD patients because it implements 
backward walking and rhythmic movement in coordination with a partner. While several 
studies have shown improvement in quality of life and mood in PD patients with a Tango 
intervention, there is conflicting evidence among studies with various study designs, 
interventions, symptom parameters, and outcome measures making it difficult to provide 
recommendations to patients. This will be the first study to investigate the effects of a 
dance intervention on sleep quality in patients with PD, applying an adapted Tango 
program similar to those used in previous studies. 
 
Clinical and/or public health significance 
PD is a progressive neurodegenerative disease with no cure. In the US alone, the 
economic impact of PD is estimated to exceed $34 billion per year and continues to 
increase.84 This highlights the importance of implementing affordable non-pharmacologic 
treatments of PD symptoms, such as Tango dance exercise. Researchers studying non-
pharmacologic interventions for PD have shown significant improvements in motor 
function, cognition, and quality of life with exercise therapy.  
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Adherence to exercise regimens can often be challenging for elderly patients with 
progressive neurological impairment. Studies have reported high patient satisfaction and 
enjoyment with Tango interventions that may lead to greater adherence long-term. Dance 
exercise has been shown to have superior responses in motor symptoms and functional 
mobility in PD patients when compared to traditional exercises, leading to improvement 
in quality of life, safety, and independence. If the results of this study reveal positive 
effects of Tango on sleep quality, clinicians may be able to recommend Tango-style 
dance exercise as an intervention that targets sleep disturbances that are underreported, 
underdiagnosed, and untreated in many patients. Furthermore, offering non-
pharmacologic treatment options such as Tango may improve non-motor symptoms of 
PD while lowering healthcare costs for PD patients worldwide.  
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APPENDIX 
Appendix 1: Parkinson’s Disease Sleep Scale (PDSS-2)85 
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Appendix 2: Beck Depression Inventory-II (BDI-II). Copyright by Pearson 1996. 
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